ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1326-1331

  El Sharkawi, Dima ^a   Ali, Akbar ^a   Evans, Catherine M ^a   Hills, Robert K ^b   Burnett, Alan K ^b   Linch, David C ^a   Gale, Rosemary E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Acute myeloid leukemia; ASXL1; Mutation; Prognostic significance

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASXL1 GENE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; FRAMESHIFT MUTATION; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; NONSENSE MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; GENETICS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ASXL1 PROTEIN, HUMAN; BIOLOGICAL MARKER; REPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; REPRESSOR PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901308956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.833332     Document Type: Article

References (26)

1. Patel JP, Levine RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012;2012:28-34
2. Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia-where are we and what is its role in patient management. Br J Haematol 2013;160:303-320
3. Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated wiThpoor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5:12
4. Hoischen A, van Bon BW, Rodriguez-Santiago B, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 2011;43:729-731
5. Fisher CL, Randazzo F, Humphries RK, et al. Characterization of Asxl1, amurine homolog of Additional sex combs, and analysis of the Asx-like gene family. Gene 2006;369:109-118. (Pubitemid 43327337
6. Lee SW, Cho YS, Na JM, et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating wiThHP1 and LSD1. J Biol Chem 2010;285:18-29
7. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193
8. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia wiThadditional sex comblike 1 (ASXL1) mutations. Blood 2010;116:4086-4094
9. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients wiThprimary cytogenetically normal AML within the ELN favorable genetic category. Blood 2011;118:6920-6929
10. Paschka P, Schlenk RF, Herzig J, et al. ASXL1 mutations predict for resistance to chemotherapy and inferior outcome in younger adult patients wiThacute myeloid leukemia (AML): A study of the German-Austrian AMLSG. Blood 2011;118(Suppl. 1): Abstract 412
11. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089
12. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value. Haematologica 2012;97:388-392
13. Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML wiThintermediate risk karyotype and are independently associated wiThan adverse outcome. Leukemia 2013;27:82-91
14. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients wiThacute myeloid leukemia. Blood 2011;118:5593-5603
15. Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010;24:469-473
16. Fernandez-Mercado M, Yip BH, Pellagatti A, et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) wiThnormal cytogenetics. PLoS One 2012;7: E42334
17. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults wiThacute myeloid leukemia. Results of the Medical Research Council's 10ThAML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311-2318
18. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311
19. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 2010;28: 586-595
20. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients wiThacute myeloid leukemia. Blood 2007;110:1262-1270. (Pubitemid 47281424
21. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction wiThNPM1 mutations in a large cohort of young adult patients wiThacute myeloid leukemia. Blood 2008;111:2776-2784
22. Green CL, Evans CM, Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients wiThacute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010;116:2779-2782
23. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409-412
24. Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients wiThacute myeloid leukemia: Impact of double CEBPA mutations and the interaction wiThFLT3 and NPM1 mutations. J Clin Oncol 2010;28:2739-2747
25. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278
26. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92: 2322-2333. (Pubitemid 28452973